Roche’s Tecentriq fails to boost survival in bladder cancer study

Roche’s immunotherapy Tecentriq has failed to significantly improve overall survival compared to chemotherapy in pre-treated patients with advanced bladder cancer, marking a major setback for the drug.

Spotlight

Spotlight

Related News